Epstein Secrets

the COI risk has been well-addressed and can permit this investment to go forward. Thank you for your consideration and assistance. Kind regards, David Levy, '92, SM '87, SB '87 please note The information contained in this communication is confidential, may be attorney-client privileged, may constit

cal groundwork for our technology, which is complete and all the patents are filed. As such, there is no more work conducted on the topic at MIT, by Shuguang or anyone else. Furthermore, our agreement states that even if there were any additional theoretical leamings, they would belong to MIT. And, 2) cr

OI risk has been well-addressed and can permit this investment to go for=ard. Thank you for your consideration and assistance. Kind regards, =br> David Levy, Ph.D. '92, SM '=7, SB '87 2 EFTA_R1_01646626 EFTA02513455 4> please note The information contained in this communicati=n is confidential, ma

al groundwork for our tech=ology, which is complete and all the patents are filed. As such, there is =o more work conducted on the topic at MIT, by Shuguang or anyone else. Fur=hermore, our agreement states that even if there were any=additional theoretical learnings, they would belong to MIT. And, 2) =

OH2 Laboratories Re-engineering Drug Discovery Company Overview February 2015 David Levy, Ph.D. General Manager and Chairman OH2 Laboratories, LLC Confidential and Proprietary EFTA00586577 Introductions: The OH2 Laboratories Team

nt & CEO, Gen9 GM, Life Technologies, VP and GM, BioTrove Steve Yang, Ph.D. Director, Sentilaia Consultant, McKinsey Scientific Advisory Board Shuguang, Zhang, Ph.D. Lab Head, MIT 170 publication 36 patents and pending patents Founder, 3D Matrix Many awards Robert Langer, D.Sci. David H. Koch